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Abstract
Background: Chronic hepatitis E represents an emerging challenge in organ transplantation, as there are currently
no established treatment options for patients who fail to clear hepatitis E virus (HEV) following reduction of
immunosuppressive therapy and/or treatment with ribavirin. Sofosbuvir has shown antiviral activity against HEV in
vitro but clinical utility in vivo is unknown.
Case presentation: We describe a 57-year-old liver transplant recipient with decompensated graft cirrhosis due to
chronic hepatitis E. Reduction of immunosuppressive treatment as well ribavirin alone for 4 months did not result in
viral clearance. Add-on of sofosbuvir for 6 months was associated with HEV RNA becoming undetectable in plasma.
However, sustained viral clearance could not be achieved.
Conclusions: Sofosbuvir may have some antiviral activity against HEV when added to ribavirin. However, this did
not suffice to yield sustained viral clearance. Our well-characterized observation emphasizes the need for new
treatment options to cure chronic hepatitis E in the setting of organ transplantation.
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Background
Hepatitis E virus (HEV) is a leading cause of acute hepa-
titis and jaundice worldwide [1]. In low-income areas,
HEV is transmitted via the fecal-oral route and associ-
ated with high morbidity and mortality, especially among
pregnant women infected with HEV genotype 1. In mid-
dle- and high-income areas, HEV infection represents a
zoonosis acquired primarily through the consumption of
raw or undercooked pork or game meat. In this setting,
HEV genotype 3 infection is, in most cases, responsible
for self-limited disease. However, in the context of im-
munosuppression, chronic hepatitis can develop and
evolve to cirrhosis in up to 10% of patients within a
short period of 2 years.
Chronic HEV infection after transplantation is managed
following a stepwise approach: First, immunosuppressive
therapy is reduced if possible, resulting in viral clearance
in about one third of cases. Second, ribavirin (RBV)
monotherapy represents the current standard of care,
resulting in viral clearance in 78% of patients treated for
12 weeks ([1] and references therein). Most patients elim-
inate HEV upon retreatment for a longer period. However,
some patients do not achieve sustained viral clearance even
after repeated and prolonged treatment courses or develop
resistance to RBV. Novel antiviral strategies are needed for
these patients.
Sofosbuvir (SOF), a highly potent hepatitis C virus
(HCV) polymerase inhibitor, was shown to inhibit HEV
genotype 3 replication in vitro, with an additive effect
when combined with ribavirin [2]. Here, we report the
outcome of SOF and RBV combination therapy in a liver
transplant recipient with decompensated graft cirrhosis
due to chronic hepatitis E and an insufficient response
to RBV alone.
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Case presentation
A 57-year-old Caucasian male patient received a liver
transplant in 1998 for alcoholic cirrhosis and hepatocel-
lular carcinoma. In 2006, diffuse large B-cell lymphoma
(post-transplant lymphoproliferative disease) was diag-
nosed and successfully treated with chemotherapy. The
patient’s previous medical history also included psychiatric
illness and post-traumatic epilepsy. His maintenance im-
munosuppressive treatment consisted of tacrolimus
(trough levels 5–6 μg/l) and prednisone 5mg qd.
Since 2014, routine control exams revealed slight
intermittent transaminase elevation, attributed to sus-
pected alcohol consumption. In August 2016, the patient
presented with ascites and laboratory evidence of graft
dysfunction (INR 1.3, albumin 34 g/l, total bilirubin
47 μmol/l, creatinine 99 μmol/l), without any signs of en-
cephalopathy. Child-Pugh stage and MELD score were
B9 and 14, respectively. Transaminases were moderately
elevated (ALT 63 U/l, AST 110 U/l) and associated with
some degree of cholestasis (alkaline phosphatase 240 U/
l, γ-GT 502 U/l). Hepatitis B and hepatitis C as well as
cytomegalovirus infections were ruled out by PCR.
There was no significant increase in Epstein-Barr virus
DNA which remained in the usual range for the patient
(24,000 cp/ml).
Serology for both anti-HEV IgM and IgG was positive
and so was PCR for HEV RNA in plasma (7.0 log10 IU/ml).
Sequence analyses revealed infection with rabbit HEV
(genotype 3ra) [3]. Positive HEV RNA could be found
retrospectively in a stored serum sample from 2014, con-
firming the diagnosis of decompensated graft cirrhosis due
to chronic hepatitis E.
Tacrolimus was reduced to yield trough levels around
2 μg/l, along with prednisone 5 mg qd. However, as HEV
RNA did not decrease, RBV was introduced in September
2016, with trough levels between 1129 and 3700 ng/ml.
Under this treatment, liver function tests normalized and
there was a complete resolution of ascites. HEV RNA
dropped but reached a plateau at 3 log10 IU/ml after 12–
16 weeks of RBV therapy (Fig. 1). Thus, SOF 400mg qd
was added on a compassionate use basis from February to
July 2017, i.e. for a total of 24 weeks.
Shortly after SOF introduction, HEV RNA became un-
detectable in plasma and remained so throughout the
period of combination therapy (Fig. 1). Trough levels of
the major SOF metabolite GS-331007 were in the ex-
pected concentration range for a patient with moderately
impaired renal function (332–1966 ng/ml). HEV RNA in
stool became negative 2 months after the introduction of
SOF but a positive result was observed 2–3 months later,
towards the end of combination therapy. In July 2017,
SOF was stopped. Despite the maintenance of RBV, this
resulted in the reappearance of HEV RNA in plasma and
stool. After stop of RBV at the end of February 2018,
HEV viremia remained relatively low for about 3 months
(range, 3.7–4.8 log10 UI/ml) but increased again in-
creased significantly to 6.1 log10 IU/ml in July 2018.
Hence, RBV treatment was resumed in August 2018,
with a slow decline in HEV RNA in plasma and stools,
which both became undetectable at the end of Novem-
ber 2018, i.e. after more than 3months (Fig. 1). The pa-
tient is now well and still under RBV treatment at the
time of writing of this report in January 2019.
Sequencing of the polymerase region of open reading
frame 1 in plasma samples obtained before (August
2016) and after RBV treatment (July 2018) revealed, as
expected for rabbit HEV (genotype 3ra), a preexisting ly-
sine in amino acid position 1634, which persisted
throughout the observation period. Interestingly, among
other amino acid changes observed, selection of an as-
paragine instead of a lysine was noted in position 1383
(K1382 N). Both the preexisting lysine in position 1634
Fig. 1 Evolution of hepatitis E virus (HEV) RNA in plasma (filled dots and lines) and stool (yellow triangles, dotted lines) over time. The thin grey
line denotes the lower limit of detection of the PCR assay. RBV, ribavirin; SOF, sofosbuvir
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and the selected asparagine in position 1383 had previ-
ously been identified in patients with RBV failure
(reviewed in ref. [4])
To conclude, SOF appeared to exert some antiviral ef-
fect during combination therapy, resulting in negativa-
tion of HEV RNA in plasma. However, sustained viral
clearance could not be achieved.
Discussion and conclusion
There are currently no approved or recommended treat-
ment options for solid organ transplant recipients with
chronic hepatitis E who do not achieve sustained viral
elimination after reduction of immunosuppressive treat-
ment and prolonged or repeated courses of RBV [1].
Pegylated interferon-α was not considered to be an op-
tion in our patient. SOF exerts antiviral activity against
HEV in vitro, which is, however, significantly lower than
its activity against HCV [2]. Six cases involving the use
of SOF in chronic hepatitis E have been reported so far,
with mixed results: HEV clearance in two patients [5, 6],
some antiviral effect but without sustained viral clear-
ance in three others [7–9], and a lack of antiviral effect
in one [10]. Of note, SOF was administered without
RBV in the latter and the frequency of HEV RNA mea-
surements was low.
In our well-characterized case report, including quan-
titative PCR for HEV RNA in plasma and stool, viral se-
quence analyses, as well as therapeutic drug monitoring
for ribavirin and the major sofosbuvir metabolite
GS-331007, SOF also appeared to have some antiviral ef-
fect against HEV when added to RBV. However, this was
not sufficient to yield sustained viral clearance, as pre-
saged by the reappearance of HEV RNA in stool towards
the end of antiviral combination therapy [1]. Clearly,
more studies are required to draw firm conclusions on
any clinically useful activity of SOF against HEV in vivo.
In conclusion, this clinical case emphasizes the difficulty of
treating patients chronically infected with HEV in the setting
of an insufficient response to RBV. The burden of chronic
hepatitis E is probably still underestimated and clinicians will
likely face growing numbers of such difficult-to-treat cases.
Given the rapid progression to cirrhosis, new treatment op-
tions for chronic hepatitis E should be prospectively studied
to improve its management.
Abbreviations
HCV: Hepatitis C virus; HEV: Hepatitis E virus; RBV: Ribavirin; SOF: Sofosbuvir
Acknowledgments
We gratefully acknowledge Dr. Diana Brainard and the team from Gilead
Sciences for providing SOF on a compassionate use basis as well as the
molecular diagnostics laboratory of the Institute of Microbiology at the
CHUV for quantitative HEV RNA testing and the laboratory of the Division of
Clinical Pharmacology for measurements of RBV and GS-331007 levels.
Funding
This study was supported by Swiss National Science Foundation grant
31003A_179424 to DM. The funding body had no role in the design of the study,
the collection, analysis and interpretation of data, or in the writing of the manuscript.
Availability of data and materials
All data generated and analyzed during this study are included in this
published article.
Authors’ contributions
MF, MP, DM and JV cared for the patient. MF, JG, RS, HC, CM, MP, DM and JV
analyzed the data and wrote the manuscript. All authors read and approved
the final manuscript.
Ethics approval and consent to participate
Not applicable.
Consent for publication
A written informed consent was obtained from the patient for the
publication of the case report and the accompanying figure. A copy of the
written consent is available for review by the Editors.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Division of Gastroenterology and Hepatology, Centre Hospitalier
Universitaire Vaudois, Rue du Bugnon 46, CH-1011 Lausanne, Switzerland.
2Division of Gastroenterology and Hepatology, Institute of Microbiology,
Lausanne, Switzerland. 3Division of Clinical Pharmacology, Centre Hospitalier
Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland.
4Transplantation Center, Centre Hospitalier Universitaire Vaudois, University of
Lausanne, Lausanne, Switzerland. 5Present address: Institute of Liver Studies,
King’s College Hospital, London, UK.
Received: 2 February 2019 Accepted: 15 May 2019
References
1. EASL Clinical Practice Guidelines on hepatitis E virus infection. J Hepatol.
2018;68:1256–71.
2. Dao Thi VL, Debing Y, Wu X, Rice CM, Neyts J, Moradpour D, Gouttenoire J.
Sofosbuvir inhibits hepatitis E virus replication in vitro and results in an additive
effect when combined with ribavirin. Gastroenterology. 2016;150:82–5.
3. Sahli R, Fraga M, Semela D, Moradpour D, Gouttenoire J. Rabbit HEV in
immunosuppressed patients with hepatitis E acquired in Switzerland. J
Hepatol. 2019;70:1023–5.
4. Todt D, Meister TL, Steinmann E. Hepatitis E virus treatment and ribavirin
therapy: viral mechanisms of nonresponse. Curr Opin Virol. 2018;32:80–7.
5. Drinane M, Wang XJ, Watt K. Sofosbuvir and ribavirin eradication of
refractory hepatitis E in an immunosuppressed kidney transplant recipient.
Hepatology. 2019;69:2297–9.
6. Poliquin M, Machouf N, Mokhtari Z, Houchet E, Murphy D, Andonov A, et al.
Sofosbuvir and ribavirin for 24 weeks in an HIV-HEV coinfected cirrhotic patient
[abstract]. 16th European AIDS Conference, Milan, Italy, October 25-27, 2017.
7. Van der Valk M, Zaaijer HL, Kater AP, Schinkel J. Sofosbuvir shows antiviral activity
in a patient with chronic hepatitis E virus infection. J Hepatol. 2017;66:242–3.
8. Todesco E, Demeret S, Calin R, Roque-Afonso AM, Thibault V, Mallet V, et al.
Chronic hepatitis E in HIV/HBV coinfected patient: lack of power of
sofosbuvir-ribavirin. AIDS. 2017;31:1346–8.
9. Todesco E, Mazzola A, Akhavan S, Abravanel F, Poynard T, Roque-Afonso
AM, et al. Chronic hepatitis E in a heart transplant patient: sofosbuvir and
ribavirin regimen not fully effective. Antiviral Ther. 2018;23:463–5.
10. Donnelly MC, Imlach SN, Abravanel F, Ramalingam S, Johannessen I, Petrik J,
et al. Sofosbuvir and daclatasvir anti-viral therapy fails to clear HEV viremia
and restore reactive T cells in a HEV/HCV co-infected liver transplant
recipient. Gastroenterology. 2017;152:300–1.
Fraga et al. BMC Gastroenterology           (2019) 19:76 Page 3 of 3
